Provided by Tiger Trade Technology Pte. Ltd.

Stoke Therapeutics, Inc.

25.62
-0.3900-1.50%
Post-market: 25.620.00000.00%19:30 EDT
Volume:848.62K
Turnover:21.88M
Market Cap:1.65B
PE:-7.69
High:26.46
Open:26.46
Low:25.45
Close:26.01
52wk High:40.22
52wk Low:20.32
Shares:64.53M
Float Shares:49.01M
Volume Ratio:0.61
T/O Rate:1.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3325
EPS(LYR):-0.1163
ROE:-61.10%
ROA:-35.87%
PB:4.78
PE(LYR):-220.36

Loading ...

Stoke Therapeutics CMO Barry Ticho Disposes of USD 208,707 in Common Shares

Reuters
·
Aug 06

Stoke Therapeutics to Present at Canaccord Genuity Annual Growth Conference

Reuters
·
Aug 05

EyePoint Pharmaceuticals Q2 Revenue Drops on Lower License Income

Reuters
·
Aug 05

Entrada Therapeutics Q2 Net Loss Narrows on Lower Costs

Reuters
·
Aug 05

Kymera Therapeutics Q2 Collaboration Revenue More than Doubles, Beats Estimates

Reuters
·
Aug 05

Niagen Bioscience Q2 Net Sales Fall, Missing Estimates

Reuters
·
Aug 05

Analysts Are Bullish on These Healthcare Stocks: Stoke Therapeutics (STOK), Fortrea Holdings Inc. (FTRE)

TIPRANKS
·
Aug 04

Stoke Therapeutics Files for At-the-Market Offering of up to $200 Million in Stock

Reuters
·
Aug 04

Stoke Therapeutics - May Offer up to $200 Mln in Common Stock - SEC Filing

THOMSON REUTERS
·
Aug 04

Stoke Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 04

Stoke Therapeutics Q2 Revenue Falls 33% on Lower Collaboration, Licensing Income

Reuters
·
Aug 04

Stoke Therapeutics Q2 FY26 Net Loss Widens to $61.62 Million; Revenue Falls to $9.33 Million

Reuters
·
Aug 04

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

THOMSON REUTERS
·
Aug 04

Stoke Therapeutics Q2 EPS USD -0.93

THOMSON REUTERS
·
Aug 04

Press Release: Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates

Dow Jones
·
Jul 28

Stoke Therapeutics Schedules Webcast, Call on Q2 Business and Financial Update

Reuters
·
Jul 28

Can Stoke Therapeutics (STOK) Be A Bargain As Its New CSO Reshapes The Story?

Simply Wall St.
·
Jul 22

Stoke Therapeutics Chief Scientific Officer Thomas Mccauley Files Initial Beneficial Ownership Statement

Reuters
·
Jul 18

Stoke Therapeutics Grants CSO Mccauley Options for 225,000 Shares at $29.91 Each

Reuters
·
Jul 17

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Oncolytics Biotech (ONCY)

TIPRANKS
·
Jul 14